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Background: Experts express reluctance to hospitalize patients with borderline personality 
disorder (BPD) for more than a few days, arguing that extended inpatient care leads to deterioration and 
adverse events. To date, there is no empirical support for these assertions.  Aims: The current study 
examined the assumption of iatrogenic effects among BPD adults.  Methods: Clinically significant and 
reliable change in symptoms, functional capacities, and adverse events were quantified for both 
inpatients with BPD (n=245) and a well-matched inpatient reference (n=220) sample. Latent growth 
curve (LGC) models were used to evaluate moderators of the trajectory of PHQ-9 depression scores over 
the course of hospitalization.  Results: Large effect size improvements were observed in depression, 
anxiety, suicidal ideation and functional disability among patients with BPD (Cohen’s d ≥ 1.0) and those 
in the reference sample (Cohen’s d ≥.80). Clinical deterioration and adverse events were rare (occurring 
in no more than 1.1% of BPD and reference patients on any outcome) with no difference across patient 
cohorts. BPD diagnosis failed to influence the trajectory of continuous depression severity. Rather, trait 
emotion dysregulation was associated with initial depression severity. Conclusions: Twenty-five years 
ago it was assumed that adults with BPD could not benefit from psychiatric treatment. Today there are a 
number of effective evidence-based outpatient treatments for BPD, but beliefs about extended 
inpatient treatment have changed little. Current results indicate that extended inpatient treatment can 
result in significant and clinically meaningful symptomatic and functional improvement in BPD patients 
without iatrogenic effects. 
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Borderline personality disorder (BPD) is the most extensively studied personality disorder (1-3); 
however, knowledge gaps persist, especially in the area of inpatient treatment course and outcome.  
This gap is particularly problematic because 1. Adults with BPD utilize inpatient and emergency 
department services at a higher rate than any other psychiatric group and far more than individuals with 
depression (4), and 2. Psychiatry is polarized over the utility of extended hospitalization for adults with 
BPD. Many BPD experts warn against hospitalizing patients with BPD for more than a few days due to 
concerns that extended hospitalization will lead to significant deterioration (5-9). Dawson and 
MacMillan warn clinicians never to hospitalize borderline patients (5), while Paris strongly advises 
against hospitalization, concluding that hospital admissions are designed to treat episodic mood 
disorders and psychosis, but not persistent mood or suicidal conditions (9).  Paris has a point—the vast 
majority of short-term psychiatric units in the US and Canada are designed for stabilization and may not 
be suitable for BPD patients; however, the tautology carelessly extends beyond acute hospital units and 
ignores the existence of extended hospital programs in European countries and the US.  Further, such 
provocative proclamations appear to be based purely on anecdotal evidence, given the absence of 
published scientific evidence of functional variations during the course of extended hospital treatment, 
or in particular demonstrating deterioration in functioning in patients with BPD. Complicating matters, 
practice guidelines (10-12) specifically include indications for hospitalization (in the context of stepped-
care based on least restrictive, cost-effective care for current functional impairment). The American 
Psychiatric Association Practice Guideline for the Treatment of Patients with Borderline Personality 
Disorder (10) advances a set of indications for extended hospitalization:  
1. Persistent and severe suicidality, self-destructiveness, or nonadherence to outpatient 
treatment or partial hospitalization, 2. Comorbid refractory axis I disorder (e.g., eating 
disorder, mood disorder) that presents a potential threat to life, 3. Comorbid substance 
abuse or dependence that is severe and unresponsive to outpatient treatment or partial 
hospitalization, 4. Continued risk of assaultive behavior toward others despite brief 
hospitalization, and 5. Symptoms of sufficient severity to interfere with functioning, work, or 
family life that are unresponsive to outpatient treatment, partial hospitalization, and brief 
hospitalization (pg. 13).   
While the APA guideline for extended hospitalization is logical and consistent with the stepped-care 
model, the advice appears based on clinical wisdom, to prevent further deterioration and/or death, 
rather than based on evidence that extended hospitalization is an effective intervention for individuals 
diagnosed with BPD. 
Absent empirical evidence, contemporary clinicians have no way of assessing the relative merits 
of extended hospital care for BPD.  Is it a potential iatrogenic disaster (alternatively, as some experts 
insist, a costly inert ingredient that postpones effective care) or can it be an effective treatment option?  
The current study examined symptom trajectories including remission and deterioration rates on 
measures of depression, anxiety, suicidal ideation, functional disability, and well-being among 
psychiatric inpatients with BPD (n=245) compared to matched reference inpatients (n=220).  Incidents of 
suicide attempts and non-suicidal self-injury (NSSI) during hospitalization were compared as direct 
behavioral indicators of deterioration. 
Hypotheses 
If Iatrogenic effects are prevalent among BPD inpatients, results would indicate elevated 
severity of symptoms and impairment in functioning with marked spikes in symptom severity for BPD 
patients measured at bi-weekly intervals, and flat treatment response (higher initial symptom severity, 
limited improvement) relative to a reference inpatient sample.  Similarly, remission rates should be 
substantially lower for the BPD cohort compared to a matched reference sample, particularly in light of 
the adverse impact that co-occurring personality disorders can have on remission rates from major 
depression (13), By contrast, a reference inpatient sample would be expected to evidence large effect 
size reductions in symptoms, and improvement in functioning, consistent with recent studies from this 
inpatient setting (14-17). In the event that BPD patients evidenced equivalent rates of improvement 
and/or deterioration to the reference sample, we planned to explore baseline moderators of depression 
change (BPD diagnosis, substance use disorder, history of interpersonal trauma, emotion regulation). 
 
Methods 
Treatment Characteristics  
Services were provided (June 2012-September 2015) through a specialized, extended inpatient 
psychiatric facility in the United States. Treatment programming was organized around a mentalization-
based therapeutic model (18) that informed all aspects of care including medication management, 24-
hour nursing care, psycho-educational groups, individual and group psychotherapy, addictions services, 
and structured interpersonal and recreational activities. Delivery of multimodal interventions was 
intensive with an average of 59.4 hours of available programming per week.    
Procedures  
Data were collected as part of the hospital’s ongoing Adult Outcomes Project to assess 
treatment response (19). Measures were collected within 72 hours of admission and were re-
administered every 14 days during hospitalization and at point of discharge.  This study was approved by 
the Institutional Review Board of Baylor College of Medicine.  Propensity score matching (PSM) was 
used to match 245 BPD patients receiving between two and eight weeks of inpatient care with a cohort 
of reference patients from this facility without BPD. A propensity score pairs subjects from the case 
group (BPD) with subjects from the reference group such that the overall distribution of baseline 
potential confounds is similar across groups (20,21).  This procedure increases the probability that 
results are due to primary dependent variables (in this case the presence/absence of BPD) rather than 
baseline confounds (20). The PSM procedure identified 220 reference inpatient controls that matched 
on age, gender, history of prior psychiatric hospitalization, number of psychiatric disorders, and length 
of hospitalization. Average length of stay (LOS) for the total sample was 40.7 days (SD= 13.9). Exclusion 
criteria were restricted to length of stay ≤ 14 days and ≥ 57 days (consistent with the design of the 
treatment program). Characteristics of the BPD and matched reference patients are provided in Table 1. 
Measures 
Demographic variables were assessed using a standardized patient information survey (15). 
Trauma-related events were assessed using a modified 14-item version (22) of the Stressful Life Events 
Screening Questionnaire (SLESQ-R). A large-scale psychometric study of the SLESQ-R (23) found 
adequate internal consistency (Ordinal alpha = .87). Psychiatric disorders including personality diagnoses 
were assessed using research versions of the Structured Clinical Interview for DSM-IV Disorders (SCID-
I/II). The SCID-I (24) and SCID II (25) were administered by master’s level researchers after reviewing 
pertinent psychiatric and psychosocial evaluations and consultation with the attending psychiatrist.  
Patient Health Questionnaire scales for depression (PHQ-9) and generalized anxiety (GAD-7) 
were used to monitor symptoms over the course of hospitalization. The psychometric properties of the 
PHQ-9 and GAD-7 are well-established (26,27) with average internal consistencies of α = .88 and α = .91, 
respectively, across assessments in this study. Severity of suicidal ideation was assessed using the 
Columbia Suicide Severity Risk Scale (C-SSRS: 28). A recent large-scale study (29) indicated the C-SSRS 
evidenced strong psychometric properties. The 12-item World Health Organization Disability 
Assessment Schedule 2.0 (WHO-DAS 2.0: 30) is psychometrically sound measure of illness-related 
disability (31). The WHO-DAS 2.0 demonstrated excellent stability in the current sample (α = .91). 
General well-being was monitored using the 5-item World Health Organization Well-Being Index (32: 
WHO, 1998). Review of this measure indicates adequate validity and sensitivity to change (33,34) with 
strong internal consistency in the current study (α = .91). The Difficulties in Emotion Regulation Scale 
(35) served as an index of global affect regulation in the analyses of continuous symptom change. Total 
scores are calculated as the sum of individual items (range: 36 to 180) with values below 75 interpreted 
as evidence of normative functioning. Research indicates strong psychometric properties in both non-
clinical (35) and inpatient samples (36) with adequate internal consistency in the current sample (α = 
.94).  All suicide attempts (SA) and NSSI were coded based on extant record of events as an ongoing 
internal safety and quality improvement project. Due to low prevalence rates, individual counts for SA 
and NSSI were summed over the course of hospitalization.  
Data Analysis 
Treatment Gains and Deterioration 
Therapeutic gains, symptom deterioration, and adverse events (from intake to discharge) were 
quantified through several metrics for both cohorts. Confidence intervals for within-group change and 
corresponding effect sizes provided estimates for the magnitude of expected treatment response in 
those receiving care through this facility. Clinically significant change was operationalized as discharge 
scores falling closer to the mean of a functional sample relative to the original clinical population (37). 
Finally, indices of reliable change were calculated to detect symptom fluctuations (both improvement 
and deterioration at each assessment point) exceeding those attributable to measurement error alone 
(37). Reliable change is commonly employed as a metric of patient deterioration in the existing 
treatment literature (38,39).    
Moderators of Continuous Recovery 
Latent growth curve (LGC) models were used to evaluate moderators of the trajectory of PHQ-9 
depression scores over the course of hospitalization. In this approach, patient-specific trajectories are 
aggregated to form a baseline model of overall recovery. Predictors of patient-specific change are 
incorporated in cases where growth parameters in the baseline model provide evidence of variability in 
the trajectory of recovery across individuals. A stepped approach was used for the current analyses (40). 
First, a series of baseline models were examined to identify plausible trajectories of recovery in the full 
sample. Analyses specifying both linear and quadratic change were explored. Next, variance estimates 
from the best fit baseline model were examined to determine whether patient-specific trajectories of 
recovery varied meaningfully from those in the aggregate sample. Non-zero variance estimates suggest 
the potential for unique patterns of change associated with patient-specific factors (e.g., treatment 
response in BPD patients differs from that observed in reference patients). Assuming evidence of 
variability in latent growth parameters, patient-level factors were included to capture patterns of 
individual change. All predictors in the final model were grand-mean centered. Interaction terms were 
calculated as the product of centered component variables. Significant effects in the final solution 
reflect unique relations between patient factors and change in PHQ-9 depression, controlling for other 
variables in the model.   
Analyses were conducted using MPlus 6.1 software with maximum likelihood (ML) estimation 
(41). A notable feature of ML is the ability to accommodate cases with partially missing values. For the 
current sample, missingness in bi-weekly scores was due primarily to differences in LOS across the 8-
week treatment window (i.e., cases with longer hospital stay recorded a greater number of assessments 
than those with shorter hospitalizations). Given that (a) missing data at later assessments were a direct 
function of length of stay, and (b) length of stay was explicitly modeled in the larger analyses, data loss 
was assumed to meet standards for missing at random (MAR) and appropriate for ML estimation (42).   
Model Fit. Model adequacy was evaluated using comparative fit index (CFI), Tucker-Lewis index 
(TLI), and root-mean-square of approximation (RMSEA) values. For these analyses, CFI and TLI > .90, and 
RMSEA < .08 were considered evidence of adequate fit (43-45). CFI and TLI > .95 and RMSEA < .06 were 




Patients presenting with a diagnosis of BPD evidenced greater symptom and functional 
impairment (see Table 1) at intake relative to reference patients (all p ≤ .001), with between-group 
effects falling in the small-to-medium range. BPD patients continued to evidence incrementally greater 
impairment at discharge (all p ≤ .020), although data indicate a consistent reduction in the discrepancy 
between BPD and reference sample functioning.     
Pre- to Post-Treatment Gains 
Similar trajectories of recovery were observed across BPD and reference groups (see Fig. 1) for 
all measures over the 8-week treatment window. Absolute change from intake to discharge was 
substantial in both samples (see Table 2). Reference patients demonstrated a .81 to 1.15 standard 
deviation improvement across all clinical outcomes. Lower limits of corresponding confidence intervals 
exceeded standard benchmarks for large effects (46) with the exception of change in suicidal ideation. 
Absolute change in patients with a diagnosis of BPD was more pronounced. Point estimates of effect 
and lower limits of corresponding confidence intervals indicated, at minimum, a full standard deviation 
improvement across all outcomes. Rates of clinically significant change were comparable across groups 
(see Table 3) based on non-clinical distributions for the PHQ-9 (47), GAD-7 (27), WHO-DAS 2.0 (48), and 
WHO-5 (49). Small to medium effects were noted in the occurrence of reliable change, however, with 
BPD patients demonstrating more frequent improvement in PHQ-9 (p < .001), GAD-7 (p = .001), WHO-5 
(p < .001), and C-SSRS (p = .058) scores. Deterioration in symptoms over the course of hospitalization 
was rare, occurring in no more than 1.1% of BPD and reference patients on any outcome.   There were 
no suicide attempts for either group. Prevalence of NSSI was low for both BPD (9 of 245: 3%) and 
reference (2 of 220: 1%) samples with no overall differences (χ2=2.7, p=.10).  
Growth Models 
Baseline linear and quadratic models were examined to determine the overall shape of change 
in depression severity. Loadings for growth parameters were weighted to reflect time (in weeks) since 
admission. Growth parameters in baseline models were regressed onto LOS (mean centered) to account 
for variability in the duration of hospitalization. Bootstrapped standard errors were estimated using 500 
redraws from the original sample.  
The baseline model of linear change was poor (CFI = .829, TLI = .802, RMSEA = .133, CI90% [.122, 
.155]). Subsequent estimation of quadratic change in PHQ-9 depression evidenced adequate fit (CFI = 
.968, TLI = .939, RMSEA = .074, CI90% [.045, .104]). Parameters in this model identify a trajectory of rapid 
initial improvement with slowed but continuous recovery over time. Variance estimates indicated 
reliable differences between BPD and reference patients in PHQ-9 scores at admission (intercept: p < 
.001) but little evidence of differences in rate of initial change (slope; p = .065) or in the tapering of 
recovery over time (quadratic: p = .168).  
Estimation of the full quadratic model offered further support for homogeneity of change (see 
Supplemental Table 4). Although inclusion of patient-specific factors produced notable improvements in 
overall model fit (CFI = .975, TLI = .994, RMSEA = .044, CI90% [.023, .064]), moderating effects were 
limited to the prediction of initial depression (intercept). Alcohol/substance use disorders were 
associated with lower PHQ-9 scores at admission (β = -.126, p = .011) whereas initial depression was 
more severe among patients reporting a history of interpersonal trauma (β = .114, p = .019). BPD status 
failed to evidence independent relations with recovery parameters controlling for other variables in the 
model. An interactive effect of BPD diagnosis and initial affect dysregulation was noted, however, in the 
prediction of depression scores at admission (β = -.128, p = .011). Follow-up tests indicated elevated 
depression among BPD patients relative to reference patients only within the context of low 
dysregulation (β = .191, p = .027). Initial PHQ-9 scores were similar in BPD and reference patients 
reporting (see Figure 2) elevated emotional dysregulation (β = -.088, p = .226). Slope and quadratic 
parameters in the final model were unrelated to BPD status, trauma history, or DERS scores at admission 
(p ≥ .102).   
Discussion 
Borderline personality disorder (BPD) is characterized by emotion dysregulation, impulsivity, 
self-injurious behavior, and suicidal behavior all of which contribute to the highest emergency and 
inpatient service utilization of any psychiatric disorder (4).  The prevalence of BPD is estimated to range 
from 10 percent in outpatient clinics to between 15 and 25 percent in inpatient settings (2).  High-
quality randomized controlled trials have demonstrated the efficacy of outpatient treatment of patients 
with BPD (see Leichsenring et al, 2011 for a detailed review), such that there is an international 
consensus that the core, or primary, evidence-based treatment for BPD is psychotherapy, accompanied 
as needed by symptom-targeted, adjunctive pharmacotherapy. The broad acceptance of evidence-based 
outpatient therapy stands in stark contrast to the polarized debate regarding inpatient treatment. One 
reason for this state is the limited data on how patients respond to acute and extended inpatient 
admission.  
Prior results for extended inpatient treatment are limited to a small number of trials that 
assessed pre-post functioning but provided no insight into potential deterioration during the course of 
treatment. Several open trials utilizing inpatient cognitive behavior therapy (CBT) and inpatient 
dialectical behavior therapy (DBT) indicated fewer episodes of non-suicidal self-injury (NSSI) and 
overdose attempts than a hospitalized treatment-as-usual (TAU) group (50,51). A multi-center clinical 
trial of 207 patients with personality disorders (77% were diagnosed with BPD) indicated a slight 
advantage of intensive inpatient treatment over outpatient, day hospital and group therapies at 18-
month follow-up (52). Recent reports of hospital-based psychodynamic treatment for individuals with 
personality disorders (61% were diagnosed with BPD) demonstrated large effect size improvement in 
symptoms (ES= 1.06) between admission and discharge (53). The only published RCT of inpatient 
treatment for BPD (54) demonstrated superiority of inpatient treatment over outpatient TAU at 
termination and one-month post-termination.  By comparison, brief (5-day) inpatient treatment was 
ineffective in reducing symptoms and functional impairment at point-of discharge (55). This single study 
of brief inpatient treatment provides limited support for Paris’ assertion (9) but is far from definitive.  
On balance, findings from treatment trials support the relative effectiveness of extended inpatient 
treatment for BPD; however, the pre-post nature of past trials leave open the question of potential 
deterioration and adverse events during the course of hospitalization. This was the primary focus of our 
study. 
Contrary to the iatrogenic hypotheses, BPD patients evidenced minimal deterioration during 
hospitalization as well as large effect size improvement and reliable change scores equivalent to the 
reference sample. Suicide attempts were non-existent and NSSI rates were low for both groups. 
Furthermore, linear growth model trajectories indicated that BPD diagnosis did not impact change in 
depression severity during the course of treatment. An interactive effect of BPD diagnosis and baseline 
emotion dysregulation did emerge with respect to depression scores assessed at intake. Here, BPD 
diagnosis was associated with elevated levels of initial depression, but only within the context of low 
emotion dysregulation. Individuals presenting for treatment with high levels of baseline dysregulation 
evidenced similar depression scores, irrespective of BPD status.   
The results of growth modeling highlight the impact of the initial severity of emotion 
dysregulation on baseline depression severity, as well as differential end-point functioning. As can be 
seen in Figure 2, BPD and reference inpatients with high levels of emotion dysregulation manifested 
differential depression severity from those with lower emotion dysregulation. Emotion dysregulation, as 
we have argued elsewhere (56), may represent a cross-cutting dimension of psychopathology that exerts 
significant influence on baseline symptom expression and treatment response, regardless of primary 
diagnosis. In this vein, the NIMH RDoC initiative (57) with its emphasis on underlying cross-cutting 
dimensions of psychopathology may provide a better model for understanding patients at risk for 
attenuated treatment response. 
Finally, the large effect size improvements for BPD inpatients across symptom and functional 
domains were surprising. While beyond the scope of the study design to explore mechanisms of change, 
there are several treatment features at the study institution worth noting. First, BPD inpatients were in a 
contained and secure environment in which self-defeating and self-destructive behaviors (such as 
alcohol and drug abuse) were minimized, and medication adherence for both groups was approximately 
99% for all standing psychotropic orders. The volume of therapeutic encounters (an average of 59 hours 
of active programming per week) is far beyond community-level treatment as usual and may be a 
significant factor in treatment response. Finally, the mentalization-based treatment may have been 
particularly well-suited for the BPD sample.  
The large sample of BPD inpatients (n = 245) with research confirmed diagnoses, systematic 
assessment of treatment response, and well-matched reference sample are strengths of the current 
study. Nonetheless, several limitations are noteworthy. The sample does not include outpatient controls 
and is comprised of individuals with severe mental illness with relatively high levels of PD traits.  It is 
clear from the literature that outpatient treatment can be effective for many patients with BPD.  
However, for patients with BPD who have complex illnesses that have not responded to outpatient 
treatment, intensive extended inpatient treatment can be highly beneficial.  Finally, it is important to 
note that our study did not assess post-discharge functioning, which is a significant limitation--data are 
currently being collected on post-discharge patients.  
The expected differences between reference and BPD groups did not emerge perhaps in part 
because confounds of age, gender, history of prior psychiatric hospitalization, co-occurring psychiatric 
disorders, and length of hospitalization were controlled through the PSM procedure.  It seems plausible 
that prior observations of iatrogenic effects for BPD inpatients were due to comorbid conditions or a 
lack of structured, evidence-based treatment. With over 250 variations within the BPD diagnosis (57), it 
has long been established that two individuals diagnosed with BPD can manifest extremely different 
levels of psychopathology and treatment response—in that light, experts advocating against extended 
hospitalization of BPD patients may base such global assertions on particularly salient memories of 
adverse outcomes among a limited set of BPD inpatients (a case of Berkson’s bias). Third, some 
extended inpatient settings may induce iatrogenic effects such as those noted by Paris (9). Inpatient 
settings with a lack of clear structure and expectation inevitably lack systematic delivery of 
contemporary evidence-based treatments for BPD and thus may create invalidating environments that 
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Table 1. Background characteristics for borderline personality disorder and matched reference patients 
with effect sizes for between-group comparisonsa 
 
Reference Borderline ES 
N 220 245  
Sex (% female)* 62.7 62.4 .00 
Age* 32.7 (13.5) 28.5 (11.0) .34 
Prior Hospitalization (%)* 62.7 71.8 .10 
LOA (weeks)* 5.9 (2.0) 5.7 (2.0) .10 
Race (% minority) 11.8 11.4 .01 
Education (%)   .14 
 - High school or less 12.7 14.7  
 - Some College/A.S./Tech 39.1 50.2  
 - Bachelor’s 55.0 20.8  
 - Post-graduate  18.2 14.3  
Married (%) 21.4 15.5 .07 
DERS 99.4 (28.3) 122.5 (20.4) .95 
ETOH/Substance Dx (%) 49.1 75.5 .27 
Trauma History (%) 53.2 73.1 .21 
PHQ-9    
 - Intake 18.31 (5.52) 14.93 (7.49) .51 
 - Discharge 7.82 (6.32) 5.96 (5.89) .30 
GAD-7    
 - Intake 14.83 (5.10) 11.69 (6.11) .56 
 - Discharge 7.27 (5.65) 5.23 (4.77) .39 
WHODAS    
 - Intake 19.79 (8.97) 15.61 (9.15) .46 
 - Discharge 8.51 (7.67) 6.40 (6.70) .29 
WHO-5    
 - Intake 6.12 (4.09) 7.91 (5.78) .36 
 - Discharge 13.77 (5.36) 15.11 (5.77) .24 
C-SSRS (severity past mo)    
 - Intake 11.62 (6.86) 8.02 (7.97) .49 
 - Discharge 2.87 (5.43) 1.76 (4.65) .22 
Note: LOA = Length of Admission; DERS = Difficulties in Emotion Regulation Scale; PHQ-9 = Patient 
Health Questionnaire; GAD-7 = Generalized Anxiety Disorder 7-Item Scale; WHODAS = WHO Disability 
Assessment Schedule 2.0; WHO-5 = WHO Well-Being Index; C-SSRS = Columbia Suicide Severity Rating 
Scale – Ideation severity over the previous month 
* Indicates characteristics included in the propensity score matching (PSM) procedure 
a Effects sizes (ES) are given as φ (small = .10, medium = .30, large = .50) and g (small = .20, medium = 
.50, large = .80) for categorical and continuous variables, respectively 
Table 2. Change scores (M, SD), effect sizes, and interval estimates for improvements in borderline personality disorder and matched reference 
groups from intake to discharge 
 
Δ 95% CI t da 95% CI 
PHQ-9      
 - Reference 8.20 (7.11) [7.23, 9.16] 16.713 1.15 [0.98, 1.33] 
 - Borderline 10.16 (7.09) [9.26, 11.06] 22.25 1.43 [1.25, 1.61] 
GAD-7      
 - Reference 6.43 (6.12) [5.53, 7.33] 14.10 1.05 [0.87, 1.23] 
 - Borderline 7.62 (6.43) [6.76, 8.47] 17.53 1.18 [1.01, 1.36] 
WHODAS      
 - Reference 9.17 (8.36) [8.05, 10.29] 16.12 1.10 [0.93, 1.27] 
 - Borderline 11.36 (9.74) [10.13, 12.58] 18.26 1.17 [1.00, 1.33] 
WHO-5      
 - Reference 7.41 (6.48) [6.46, 8.36] 15.39 1.14 [0.96, 1.33] 
 - Borderline 7.79 (5.48) [7.06, 8.52] 21.04 1.42 [1.23, 1.61] 
C-SSRS (severity past mo)      
 - Reference 6.05 (7.48) [5.04, 7.05] 11.87 0.81 [0.65, 0.96] 
 - Borderline 8.65 (7.24) [7.73, 9.57] 18.54 1.19 [1.03, 1.36] 
Note: PHQ-9 = Patient Health Questionnaire; GAD-7 = Generalized Anxiety Disorder 7-Item Scale; WHODAS = WHO Disability Assessment 
Schedule 2.0; WHO-5 = WHO Well-Being Index; C-SSRS = Columbia Suicide Severity Rating Scale – Ideation severity over the previous month 
a Effects sizes for within-subject tests (small = .20, medium = .50, large = .80) standardized using the standard deviation of change from intake to 
discharge to permit calculation of corresponding interval estimates.  
 
Table 3. Patient percentages and between-group effects for clinically significant change,a reliable 
change, and symptom exacerbation 
 




 - Clinically Sig Change 62.9 63.5 .006 
 - Reliable Change 40.0 70.5 .307 




 - Clinically Sig Change 67.6 63.5 .043 
 - Reliable Change 43.8 58.9 .151 




 - Clinically Sig Change 69.4 62.9 .069 
 - Reliable Change 51.4 59.2 .078 




 - Clinically Sig Change 78.1 79.6 .018 
 - Reliable Change 57.1 75.4 .194 
 - Exacerbation 0.9 1.1 - 
C-SSRS (severity past mo) 
  
 
 - Reliable Change (w/pre-ideation) 59.8 70.0 .108 
 - Exacerbation 0.0  0.4 - 
Note: PHQ-9 = Patient Health Questionnaire; GAD-7 = Generalized Anxiety Disorder 7-Item Scale; 
WHODAS = WHO Disability Assessment Schedule 2.0; WHO-5 = WHO Well-Being Index; C-SSRS = 
Columbia Suicide Severity Rating Scale – Ideation severity over the previous month; reliable change in 
severity of suicidal ideation restricted to the subset of reference (25.0%) and borderline (40.4%) patients 
acknowledging ideation at intake 
a Criteria for clinically significant change in reference patients were scores at or below 6.0, 6.0, and 7.0 
on the PHQ-9, GAD-7, and WHO-DAS, and 11.0 or above for the WHO-5; criteria for PBD patients were 
scores at or below 8.0, 7.0, and 9.0 on the PHQ-9, GAD-7, and WHO-DAS, and 10.0 or above for the 
WHO-5; clinically significant change for C-SSRS was not calculated given the absence of non-clinical 
scores for this measure 
b Small: φ = .10, Medium: φ = .30, Large: φ = .50 
 
 
Supplemental Table 1. Parameter estimates for latent growth model of change in PHQ-9 depression 
Intercept (Β0 = 16.864, p < .001) Slope (Β1 = -3.321, p < .001) Quadratic (Β2 = .265, p < .001) 
 
β b se β b se β b se 
LOS -.020 -.016 .039 .402 .058 .025 -.414 -.007 .004 
BPDb .051 .057 .065 .005 .002 .036 .010 .000 .005 
SUDb -.126 -.144 .057 .018 .007 .037 -.062 -.003 .005 
Traumab .114 -.131 .056 -.052 -.002 .033 .062 -.003 .005 
DERSc .601 .247 .023 -.148 -.011 .014 .005 .000 .002 
BPD x SUD .010 .002 .011 .038 .003 .007 -.031 .000 .001 
BPD x Trauma -.011 -.003 .012 .040 .003 .007 -.060 -.001 .001 
BPD x DERS -.128 -.011 .004 .131 .002 .003 -.117 .000 .000 
Note: PHQ-9 = Patient Health Questionnaire; LOS = length of admission; BPD = borderline personality disorder (0 = no, 1 = yes); SUD = 
substance/alcohol use disorder (0 = no, 1 = yes); Trauma = history of interpersonal trauma (0 = no, 1 = yes); DERS = Difficulties in Emotion 
Regulation Scale. 
a Bolded figures p ≤ .05; Bolded/underlined figures p ≤ .01 
b Dichotomous indicators for borderline personality diagnosis, alcohol/substance use diagnosis, and history of interpersonal trauma were 
rescaled by multiplication of a constant (x10) to optimize analysis of the covariance matrix 
















































































Figure 1. Observed scores for reference and borderline personality 
disorder patients. 
● ●   Borderline 
○ ○   Reference 
Note: PHQ-9 = Patient Health Questionnaire; GAD-7 = Generalized 
Anxiety Disorder 7-Item Scale; WHODAS = WHO Disability 
Assessment Schedule 2.0; WHO-5 = WHO Well-Being Index; C-
SSRS = Columbia Suicide Severity Rating Scale – Ideation severity 
over the previous month 
 
 
Figure 2. Interaction of emotion regulation and borderline diagnosis on the intercept of expected recovery trajectory 
 
□  □ Reference-Low DERS (-1 SD ) = 12.405-2.725(week) + .231(week2 ) 
□  □ Reference-High DERS (+1 SD )= 20.721-3.658(week) + .250(week2) 
●  ● Borderline-Low DERS (-1 SD )  = 14.525-3.286(week) + .291(week2) 
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